Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Antiproliferative and apoptotic effects of angelicin in highly invasive prostate cancer cells

Qing Wang1, You-Pei Wang2, Hong Lin3, Li-Qing Zhang4, Ling-Jian Wu5, Ling-Xia Pang1

1Function Experiment Teaching Center, Department of Laboratory, The Affiliated Eye Hospital of Wenzhou Medical University, Wenzhou 325000; 2Zhejiang Provincial Key Laboratory of Medical Genetics; 3Wenzhou Medical University, Wenzhou 325035; 4Operating Room, The First Affiliated Hospital; 5Department of Dermatological, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.

For correspondence:-  Ling-Xia Pang   Email: panglx35@gmail.com   Tel:+86-57786689885

Received: 14 January 2014        Accepted: 1 July 2015        Published: 30 August 2015

Citation: Wang Q, Wang Y, Lin H, Zhang L, Wu L, Pang L. Antiproliferative and apoptotic effects of angelicin in highly invasive prostate cancer cells. Trop J Pharm Res 2015; 14(8):1405-1411 doi: 10.4314/tjpr.v14i8.12

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To demonstrate the anti-proliferative activity of angelicin against human prostate cancer (PC-3) cells and to evaluate its mechanism
Methods: MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay was used to assess the anticancer activity (growth inhibition) of angelicin in PC-3 cells. Fluorescence microscopy using Hoechst 33258 staining and inverted phase microscopy was employed to evaluate the effect of angelicin on nuclear morphology. Flow cytometry, using propidium iodide, was employed to study cell cycle-related effects of angelicin. Apoptosis induction by angelicin was examined by annexin V/PI assay.
Results: Angelicin induced potent growth inhibitory effects in human prostate cancer (PC-3) cells in a dose-dependent manner. Angelicin-treated cells exhibited chromatin condensation which implied an early apoptotic event. Inverted phase microscopy revealed that reduction of cell population occurred with increase in the angelicin dose. Flow cytometry results showed that angelicin induced cell cycle arrest in the sub-G1 phase. Angelicin induced both early and late apoptosis in PC-3 cells following a dose-dependent pattern.
Conclusion: Angelicin inhibits the growth of PC-3 human prostate cancer cells in vitro by inducing early and late apoptosis, cell cycle arrest and chromatin condensation.

Keywords: Angelicin, Coumarin, Prostate cancer, Anticancer activity, Apoptosis, Cell cycle arrest, Chromatin condensation, Flow cytometry

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates